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Abstract
Background: The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) was
a multicenter randomized controlled trial that reported beneficial effects on cognition for a 2-year multimodal
intervention (diet, exercise, cognitive training, vascular risk monitoring) versus control (general health advice). This
study reports exploratory analyses of brain MRI measures.
Methods: FINGER targeted 1260 older individuals from the general Finnish population. Participants were 60–77
years old, at increased risk for dementia but without dementia/substantial cognitive impairment. Brain MRI scans
were available for 132 participants (68 intervention, 64 control) at baseline and 112 participants (59 intervention, 53
control) at 2 years. MRI measures included regional brain volumes, cortical thickness, and white matter lesion (WML)
volume. Cognition was assessed at baseline and 1- and 2-year visits using a comprehensive neuropsychological test
battery. We investigated the (1) differences between the intervention and control groups in change in MRI
outcomes (FreeSurfer 5.3) and (2) post hoc sub-group analyses of intervention effects on cognition in participants
with more versus less pronounced structural brain changes at baseline (mixed-effects regression models, Stata 12).
Results: No significant differences between the intervention and control groups were found on the changes in MRI
measures. Beneficial intervention effects on processing speed were more pronounced in individuals with higher
baseline cortical thickness in Alzheimer’s disease signature areas (composite measure of entorhinal, inferior and
middle temporal, and fusiform regions). The randomization group × time × cortical thickness interaction coefficient
was 0.198 (p = 0.021). A similar trend was observed for higher hippocampal volume (group × time × hippocampus
volume interaction coefficient 0.1149, p = 0.085).
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Conclusions: The FINGER MRI exploratory sub-study did not show significant differences between the intervention
and control groups on changes in regional brain volumes, regional cortical thicknesses, or WML volume after 2
years in at-risk elderly without substantial impairment. The cognitive benefits on processing speed of the FINGER
intervention may be more pronounced in individuals with fewer structural brain changes on MRI at baseline. This
suggests that preventive strategies may be more effective if started early, before the occurrence of more
pronounced structural brain changes.
Trial registration: ClinicalTrials.gov, NCT01041989. Registered January 5, 2010.
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Background
The acute need for effective strategies to prevent demen-
tia is increasingly emphasized [1]. Observational studies
have pointed out many opportunities for prevention by
addressing lifestyle, vascular, metabolic, and other modi-
fiable risk factors [2, 3]. Clinical trials are now focusing
more and more on early interventions in individuals at
increased risk for dementia and/or in preclinical disease
stages [1]. The hypothesis is that such individuals may
benefit the most from preventive interventions since
substantial, irreversible brain pathology has not yet oc-
curred. The incorporation of biomarkers in lifestyle-
based dementia prevention trials has also become in-
creasingly important, both as trial outcomes and for
assessing potential heterogeneity of intervention effects.
Many observational studies have linked modifiable life-
style, vascular, or metabolic risk factors (individually and
also multifactorial risk profiles) with structural brain
changes relevant for cognitive decline and dementia,
such as brain atrophy and white matter lesions (WML)
[3–5]. However, the effects of lifestyle interventions on
structural brain changes are still not fully clear. Only few
lifestyle-based trials have so far included brain MRI
markers. For example, randomized controlled trials
assessing physical activity [6, 7], a multimodal social en-
gagement program [8], or nutrition-related interventions
[9, 10] have reported promising effects on various gray
matter measures on MRI. These trials were conducted
either in healthy older adults or in individuals who
already had mild cognitive impairment (MCI) or pro-
dromal Alzheimer’s disease. In another randomized con-
trolled trial in hypertensive community-dwelling older
individuals, multidomain vascular care did not seem to
decrease WML progression [11].
The potential impact of pre-existing structural brain
changes on the cognitive effects of lifestyle-based inter-
ventions also needs to be investigated. This is particu-
larly important for gaining more insight into the window
of opportunity for dementia prevention.
The Finnish Geriatric Intervention Study to Prevent
Cognitive Impairment and Disability (FINGER) was the
first large randomized controlled trial to report beneficial
effects on cognition for a 2-year multidomain lifestyle
intervention among older individuals with increased risk
of dementia [12]. The FINGER trial protocol included an
exploratory brain MRI sub-study [13]. This study presents
exploratory analyses of intervention effects on changes in
MRI measures (brain volumes, cortical thickness, and
WML volume). The hypothesis was that the intervention
may slow down atrophy and WML progression. In
addition, we report post hoc sub-group analyses investi-
gating the potential differences in the intervention effects
on cognition between participants with more versus less
pronounced structural brain changes. We hypothesized
that individuals with less pronounced structural brain
changes at baseline may have more cognitive benefit from
the intervention.
Methods
Study population
The FINGER trial protocol [13], recruitment process
[14], and primary findings [12] have been previously de-
scribed in detail. In brief, the FINGER participants were
1260 individuals selected between September 7, 2009,
and November 24, 2011, from previous population-
based observational cohort studies [15–17]. The inclu-
sion criteria were as follows: age 60–77 years; increased
risk of dementia defined as ≥ 6 points on the Cardiovas-
cular Risk Factors, Aging and Dementia (CAIDE) De-
mentia Risk Score [18]; and the Consortium to Establish
a Registry for Alzheimer’s Disease (CERAD) neuro-
psychological battery [19] indicating cognitive perform-
ance at the mean level or slightly lower than expected
for age according to the Finnish population norms
[20]. Individuals with dementia, substantial cognitive
impairment, and conditions affecting safe participa-
tion/cooperation, or concurrently participating in an-
other trial were excluded.
The FINGER trial was approved by the Coordinating
Ethics Committee of the Hospital District of Helsinki
and Uusimaa, and all participants gave written informed
consent at the screening and baseline visits. Participants
in the FINGER MRI exploratory sub-study gave a separ-
ate consent for MRI scans.
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The FINGER MRI exploratory sub-study included 155
participants from 4 trial sites. These participants were
selected from the most recently recruited individuals
when MRI resources became available at each site, and if
there were no contraindications [5]. Brain scans were
conducted in connection with the baseline FINGER visit
(Fig. 1). The present study included 132 participants
with baseline MRI scans, of which 112 had a repeat scan
in connection with the 24-month FINGER visit.
Randomization and intervention
Participants were randomly assigned to the intensive
multidomain intervention group or regular health advice
(i.e., control) group (1:1 ratio). Allocations were
computer-generated in blocks of four (two individuals
randomly allocated to each group) at each of the six
study sites. Group allocation was not actively disclosed
to participants, who were also advised not to discuss the
intervention during the testing sessions. Outcome asses-
sors were blinded to group allocation, and they were not
involved in the intervention-related activities.
The multidomain intervention included four domains
[13]. The nutrition component, based on the Finnish
Nutrition Recommendations [21], included individual
and group sessions supervised by study nutritionists.
The exercise component followed international guidelines
[22] and included gym sessions and aerobic exercise led
by study physiotherapists [13]. Cognitive training was led
by psychologists and included group sessions and
computer-based individual training (web-based in-house
developed program including tasks adapted from previ-
ous protocols) [23]. Management of metabolic and vas-
cular risk factors followed national evidence-based
guidelines [24–26]. The control group received regular
health advice according to established guidelines.
Cognitive outcomes
An extended version of the neuropsychological test bat-
tery (NTB) [27] was used for cognitive assessments at
baseline and 12-month and 24-month visits. The pri-
mary trial outcome was change in the NTB total score,
calculated as a composite score based on the results
from 14 tests (Z scores standardized to the baseline
mean and SD, with higher scores indicating better
performance) [13]. Secondary outcomes included the
following cognitive domains: an executive functioning
Fig. 1 CONSORT diagram of the FINGER exploratory MRI sub-study. Consortium to Establish a Registry for Alzheimer’s Disease (CERAD)
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score calculated from Z scores for category fluency test
[19], digit span [28], concept shifting test (condition C)
[29], trail making test (shifting score B–A) [30], and a
shortened 40-stimulus version of the original Stroop test
(interference score 3–2) [31]; a processing speed score
calculated from Z scores for letter digit substitution test
[32], concept shifting test (condition A), and Stroop test
(condition 2); and a memory score calculated using Z
scores for visual paired associates test immediate and
delayed recall, logical memory immediate and delayed
recall, and word list learning and delayed recall [19, 28].
MRI assessments
Before quantitative analysis, an experienced neuroradiol-
ogist visually inspected the T1WI and FLAIR images.
Images were excluded if there were brain lesions poten-
tially affecting volumetry and/or scanning issues such as
no full-brain coverage, artifacts, intensity inhomogeneity,
and adequate gray/white matter contrast. One hundred
thirty-two scans from 3 study sites passed quality control
(all 18 scans from 1 site excluded due to acquisition is-
sues, and 5 additional scans excluded due to old brain
infarcts which may have affected the automated image
analysis). Of the 132 participants, 112 were re-scanned
in connection with the 24-month visit, and all scans
passed quality control (Fig. 1). Regular phantom scans
were performed, and quantitative measures of signal-to-
noise ratio, uniformity, and geometric distortion were
carried out at each site. The following MR systems were
used: 1.5T Avanto, Siemens at the Kuopio and Oulu sites
(3D-MPRAGE sequence, voxel size 1.2 × 1.2 × 1.2 mm3,
TR 2400 ms, TE 3.5 ms, TI 1000 ms), and 3T Ingenuity,
Philips at the Turku site (3D TFE sequence, voxel size
1.0 × 1.0 × 1.0 mm3, TR 8.1 ms, TE 3.7 ms). The same im-
aging parameters and MRI scanners were used for both
baseline and 2-year scans at each site.
Regional brain volumes and cortical thicknesses were
measured using FreeSurfer (version 5.3, http://surfer.nmr.
mgh.harvard.edu/). If geometric inaccuracy in boundaries
between white, gray matter, and CSF was present in the
automated WM segmentation, then manual editing was
conducted. FreeSurfer morphometric procedures have
been demonstrated to show good test-retest reliability
across scanner manufacturers and across field strengths
[33, 34]. Brain volumes were normalized by the total intra-
cranial volume (TIV) to account for between-person vari-
ations in head size [35].
WML volume was measured through the segmenta-
tion of WM hyperintensities according to a previously
described method [36]. The method is based on the ex-
pectation–maximization (EM) algorithm, and the seg-
mentation was done in three steps: (1) segment WM in
two classes from T1 images, representing hypointense
WM regions and normal bright WM regions; (2) using
the results of the previous step as an initialization, seg-
ment the FLAIR images to three classes: CSF, normal
brain tissue, and hyperintense voxels; and (3) using the
results of the previous step as an initialization, segment
the WM and subcortical regions from the FLAIR images
in two classes. The class with higher intensities was then
regarded as the segmentation of WM hyperintensities
[36, 37].
Statistical analysis
The baseline characteristics of the intervention and con-
trol groups in the FINGER MRI exploratory sub-study
were compared using t test or chi-square test as appro-
priate. Analyses were done using Stata software version
12 (Stata Statistical Software: Release 12. College Station,
TX: StataCorp LP). The level of statistical significance
was p < 0.05 in all analyses.
Intervention effects on changes in MRI measures (regional
brain volumes, cortical thickness, and WML volume)
Analyses included the 112 participants with repeat MRI
scans. To extract reliable volume and thickness esti-
mates for longitudinal analysis, these images were auto-
matically processed with the longitudinal stream [34] in
FreeSurfer. Differences between the intervention and
control groups in change in MRI outcomes were investi-
gated using FreeSurfer, and false discovery rate (FDR)
correction for multiple comparisons was applied.
Sub-group analyses of intervention effects on cognition in
participants with more versus less pronounced structural
brain changes at baseline
The analyses included the 132 participants with baseline
MRI scans. The following 4 MRI measures were consid-
ered: total gray matter (GM) volume, hippocampus vol-
ume, and WML volume (normalized to TIV), and a
measure of cortical thickness in AD signature regions
calculated as the average of cortical thickness in entorhi-
nal, inferior temporal, middle temporal, and fusiform re-
gions as previously described [38].
Zero-skewness log transformation was applied to
skewed NTB components. Z scores for tests at each time
point were standardized to the baseline mean and stand-
ard deviation. NTB total score and domain scores for
executive functioning, processing speed, and memory
were obtained by averaging individual NTB component
Z scores. The minimum number of necessary NTB com-
ponents was set to 8/14 for calculating NTB total score,
3/5 for executive functioning, 2/3 for processing speed,
and 3/6 for memory.
Considering within-person and between-person vari-
ability over time, mixed-effects regression models
(xtmixed command in Stata) with maximum likelihood
estimation were used to analyze the change in cognitive
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scores as a function of randomization group (intervention
versus control), time (years), MRI measure (above versus
below the median), and their interactions (randomization
group × time, group ×MRI, time ×MRI, and group ×
time ×MRI) as fixed effects. Random effects of the models
were variances and covariance of individual-level intercept
and slope. We chose to define the MRI sub-groups based
on the median value of baseline measures due to the lack
of established pathologic cutoffs, especially for at-risk gen-
eral populations such as FINGER participants.
We report the coefficient (95% CI) for the randomization
group × time ×MRI interaction as the main result, i.e., esti-
mated difference in intervention effects per year between
the MRI <median and MRI ≥median groups. We also
present the effect estimates (95% CI) within each MRI group
(the randomization group × time interaction) using the lin-
com post-estimation command after xtmixed in Stata. All
analyses were adjusted for the study site. Other covariates
were considered only if they were significantly different be-
tween the intervention and control groups at baseline.
Results
Characteristics of FINGER participants with and without
MRI data at the three study sites where brain scans were
available have been previously described in detail [5].
The MRI population was not significantly different in
demographic, clinical, and cognitive characteristics from
the population without MRI at these sites [5]. The inter-
vention and control groups in the FINGER exploratory
MRI sub-study were not significantly different in base-
line demographic, clinical, cognitive, and MRI character-
istics (Table 1).
Changes in MRI outcomes (regional brain volumes, re-
gional cortical thicknesses, and WML volume) were not
significantly different between the intervention and con-
trol groups (Table 2).
The impact of baseline MRI measures on changes in
cognition during the trial is shown in Table 3. The
randomization group × time × AD signature cortical
thickness interaction was significant for processing speed
(p = 0.021), indicating that participants with higher base-
line cortical thickness had more intervention benefit on
processing speed compared with participants with lower
cortical thickness. A similar non-significant trend was
observed for hippocampal volume (p = 0.085). No other
significant randomization group × time ×MRI interac-
tions were found.
Significant cognitive benefits (randomization group ×
time interaction) were found on NTB total score among
participants with higher baseline cortical thickness and
on processing speed among participants with higher hip-
pocampal volume, higher cortical thickness, and lower
WML volume at baseline. The differences in cognitive
outcomes between the intervention and control groups
were not statistically significant in participants with thin-
ner cortex, lower hippocampal volume, or higher WML
volume at baseline (Table 3).
Discussion
In the FINGER MRI exploratory sub-study, no signifi-
cant differences between the intervention and control
groups were found on the changes in regional brain vol-
umes, cortical thickness, or WML volume during the 2-
year trial. However, post hoc analyses suggested that
beneficial intervention effects on processing speed were
more pronounced in participants with higher baseline
cortical thickness in AD signature areas. A similar trend
was observed in participants with higher baseline hippo-
campal volume. Within-group findings by baseline MRI
measures also suggested a pattern of cognitive benefits
particularly in participants with less pronounced structural
brain changes (higher AD signature cortical thickness,
higher hippocampal volume, and lower WML volume).
The FINGER trial was designed in a public health con-
text, i.e., it targeted the at-risk segment of the general
elderly population (not patients in a clinical setting). The
intervention was started early, before the onset of de-
mentia or substantial cognitive impairment [14]. This
was the first prevention trial to select participants using
a validated dementia risk score based on several modifi-
able risk factors [18]. Overall, structural brain changes in
this at-risk population were not very pronounced during
2 years. For example, the annual rate of hippocampal at-
rophy was only slightly higher than previously reported
for healthy older individuals [39]. This may have con-
tributed to the lack of significant differences in MRI
changes between the intervention and control groups.
In addition, the FINGER multidomain intervention ad-
dressed several risk factors simultaneously. A key
principle was that multiple lifestyle changes (even of
smaller magnitude) over a longer period of time would
lead to longer-term benefits. While the intervention had
significant beneficial effects on cognition in the entire
trial population after 2 years [12], this interval may not
have been enough to see significant effects on structural
brain changes, at least not with the standard imaging
methods used in this study. The ongoing 7-year FINGER
extended follow-up will provide additional data on
longer-term changes in brain MRI measures, as well as
incident cognitive impairment and dementia.
In the present study, post hoc analyses suggested that
intervention benefits on cognition (processing speed)
were more pronounced when cortical thickness in AD
signature areas and hippocampus volume were higher at
baseline. Lower cortical thickness and hippocampus vol-
ume have been associated with poorer cognitive per-
formance even in cognitively normal older individuals
[40]. It is possible that more favorable brain MRI measure
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Table 1 Characteristics of the intervention and control groups (participants with baseline MRI measurements)
Characteristics at baseline Total, n Intervention, n = 68 Control, n = 64 p
Demographic characteristics
Age at the baseline visit (years) 132 70.3 69.8 0.50
Sex (women, %) 132 29 (42.6) 33 (51.5) 0.30
Education (years) 132 9.3 (2.9) 9.2 (2.6) 0.87
Baseline vascular factors
Systolic blood pressure (mmHg) 129 139.6 (15.9) 139.0 (14.7) 0.83
Diastolic blood pressure (mmHg) 129 79.4 (8.9) 78.6 (8.9) 0.61
Fasting plasma glucose (mmol/l) 132 6.1 (0.77) 6.1 (1.03) 0.94
Body mass index (kg/m2) 129 27.9 (3.7) 26.9 (3.4) 0.12
History of hypertension (%) 128 46 (69.7) 36 (58.1) 0.17
History of diabetes (%) 128 7 (10.6) 8 (12.9) 0.68
Baseline lifestyle factors
Physical activity 2 or more times/week (%) 128 50 (73.5) 48 (80.0) 0.38
Current smokers (%) 130 1 (1.49) 4 (6.3) 0.15
Alcohol drinking at least once/week (%) 131 31 (45.5) 30 (47.6) 0.81
Fish intake at least twice/week (%) 130 42 (61.8) 33 (53.2) 0.32
Daily intake of vegetables (%) 132 47 (69.1) 41 (64.0) 0.53
*Baseline MRI measures
Total hippocampal volume, ml 132 7.4 (4.8–9.3) 7.2 (4.7–8.7) 0.18
Total intracranial volume, ml 132 1572.9 (1108.5–2032.7) 1545.4 (957.9–1955.9) 0.42
AD signature cortical thickness, mm 132 2.8 (2.4–3.1) 2.7 (2.4–3.1) 0.61
Total GM volume, ml 132 563.3 (450.7–669.7) 559.1 (420.7–695.8) 0.62
WML volume, ml 118 10.9 (12.5) 10.9 (14.3) 0.97
Cognitive measures
Baseline
NTB total score 132 − 0.12 (0.49) − 0.009 (0.54) 0.22
Executive functioning 132 − 0.02 (0.55) − 0.05 (0.60) 0.75
Processing speed 132 − 0.15 (0.80) 0.07 (0.75) 0.10
Memory 132 − 0.18 (0.58) − 0.01 (0.60) 0.09
1 year follow-up
NTB total score 130 0.04 (0.61) 0.05 (0.58) 0.95
Executive functioning 129 0.05 (0.61) − 0.05 (0.68) 0.33
Processing speed 130 − 0.04 (0.86) 0.07 (0.76) 0.39
Memory 130 0.09 (0.76) 0.11 (0.68) 0.87
2 year follow-up
NTB total score 122 0.09 (0.67) 0.09 (0.66) 0.98
Executive functioning 122 0.08 (0.65) − 0.006 (0.70) 0.47
Processing speed 122 − 0.014 (0.94) 0.05 (0.85) 0.67
Memory 122 0.17 (0.77) 0.19 (0.78) 0.88
Values are means (SD) unless otherwise specified. Differences between the intervention and control groups were analyzed with chi-square and t tests as
appropriate. Scores on the NTB total score, executive functioning, processing speed, memory, and abbreviated memory are mean values of Z scores of the
cognitive tests included in each cognitive outcome. Higher scores indicate better performance. AD signature cortical thickness: cortical thickness in AD signature
regions calculated as the average of cortical thickness in entorhinal, inferior temporal, middle temporal and fusiform regions as previously described [38]
GM gray matter, WML white matter lesions, NTB neuropsychological test battery
*MRI values are mean (minimum–maximum). MRI measures are based on longitudinal FreeSurfer analyses
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pre-intervention may indicate higher prevention potential,
thus emphasizing the importance of starting preventive
strategies as early as possible, before substantial brain
changes and cognitive impairment have already occurred.
Post hoc findings in a trial sub-sample need to be
interpreted very cautiously [41]. The FINGER trial
has several pre-specified sub-group analyses [13], and
in addition, the present post hoc results for four MRI
measures and four cognitive outcomes were not cor-
rected for multiple testing. Thus, while results suggest
that starting prevention earlier may be associated with
beneficial effects, no claims can be made about
exactly how much cognitive benefit the intervention
would provide below or above specific cutoffs for spe-
cific brain MRI measures. While MRI measures are
related to cognitive performance, other factors such
as cognitive reserve [42] may affect the overall cogni-
tion level and response to lifestyle interventions.
Whether the window of opportunity for prevention
closes at some point, and the potential combination
of individual characteristics that may mark such a
point, remains to be determined.
The main strengths of this study are the randomized
controlled design with a multidomain intervention, lon-
ger duration than most previous cognition-focused life-
style trials, and availability of MRI scans at both baseline
and 24-month visits. The main limitation of the FINGER
MRI exploratory sub-study is the relatively small sample
size, which limited the statistical power and thus the
ability to detect significant intervention effects on MRI
measures, as well as tests of interaction in sub-group
analyses of cognitive changes by baseline MRI measures.
MRI scanners differed between sites, but this was ad-
justed for in all analyses, and the FreeSurfer morpho-
metric procedures have shown good test-retest reliability
across scanner manufacturers and field strengths [33,
34]. Although repeated cognitive testing may have led to
practice effects in all participants, focusing on the differ-
ences in cognitive change between the intervention and
control groups, and on how such differences were im-
pacted by baseline MRI measures, most likely suggested
cognitive benefits beyond practice effects.
Conclusions
The FINGER MRI exploratory sub-study did not
show significant differences between the intervention
and control groups on changes in regional brain vol-
umes, regional cortical thicknesses, or WML volume.
Post hoc sub-group analyses of cognitive intervention
benefits by more versus less pronounced structural
brain changes at baseline suggested that strategies to
prevent cognitive decline may be more effective if
started early, before the occurrence of substantial
structural brain changes.
Prevention trials with longitudinal MRI assessments
and larger neuroimaging sample sizes are needed to
Table 2 MRI measures at baseline, follow-up, and annual rate of change
MRI measures Total, n Intervention, n = 59 Control, n = 53 p
Total intracranial volume, ml 112 1581.4 (1112.4–2039.1) 1524.4 (975.5–1962.1) 0.13
Baseline
Total hippocampal volume, ml 112 7.2 (4.6–9.1) 7.0 (4.5–8.3) 0.33
AD signature cortical thickness, mm 112 2.8 (2.5–3.0) 2.8 (2.5–3.1) 0.87
Total GM volume, ml 112 576.7 (443.4–677.3) 563.4 (406.3–709.6) 0.18
WML volume, ml 100 11.9 (0.5–60.7) 11.7 (0.7–74.4) 0.95
2-year follow-up
Total hippocampal volume, ml 112 7.0 (4.3–9.1) 6.8 (4.1–8.3) 0.27
AD signature cortical thickness, mm 112 2.7 (2.5–3.1) 2.7 (2.3–3.1) 0.47
Total GM volume, ml 112 568.6 (434.4–670.4) 556.0 (414.8–698.5) 0.19
WML volume, ml 100 13.6 (0.4–59.9) 13.0 (0.5–84.9) 0.86
*Annual rate of change, % (SD)
Total hippocampal volume 112 − 1.30 (1.3) − 1.50 (2.0) 0.56
AD signature cortical thickness 112 − 0.68 (0.98) − 0.39 (1.2) 0.24
Total GM volume 112 − 0.70 (0.89) − 0.60 (1.4) 0.64
WML volume 96 7.0 (28.4) 11.6 (50.3) 0.58
MRI values are mean (minimum–maximum). All MRI measures are based on longitudinal FreeSurfer analyses. AD signature cortical thickness: cortical thickness in
AD signature regions calculated as the average of cortical thickness in entorhinal, inferior temporal, middle temporal, and fusiform regions as previously
described [38]
GM gray matter, WML white matter lesions
*Annual rate of change was calculated as (24-month value − baseline value)/(baseline value × time)
Stephen et al. Alzheimer's Research & Therapy           (2019) 11:53 Page 7 of 10
further investigate the effects of healthy lifestyle manage-
ment on brain structure, the impact of pre-existing brain
changes on cognitive benefits, and whether a window of
opportunity for dementia prevention could be defined
based on MRI measures. For example, the recent World
Wide FINGERS (WW-FINGERS) initiative is currently
Table 3 Intervention effects on cognition—sub-group analyses by baseline MRI measures
Difference between the intervention and control
groups per year (randomization group × time)
Difference between MRI >median and MRI <
median (randomization group × time × MRI)
Estimate (95% CI) p Estimate (95% CI) p
NTB total score (primary outcome)
*Hippocampal volume >median 0.056 (− 0.034–0.146) 0.225 0.030 (− 0.100–0.156) 0.668
<median 0.028 (− 0.063–0.119) 0.551
AD signature cortical thickness >median 0.092 (0.002–0.181) 0.044 0.097 (− 0.029–0.222) 0.131
<median − 0.005 (− 0.093–0.083) 0.915
*Total GM volume >median 0.018 (− 0.072–0.108) 0.701 − 0.055 (− 0.184–0.073) 0.397
<median 0.073 (− 0.020–0.160) 0.117
*WML volume >median 0.025 (− 0.063–0.113) 0.576 − 0.053 (− 0.178–0.073) 0.411
<median 0.078 (− 0.012–0.170) 0.088
Processing speed (secondary outcome)
*Hippocampal volume >median 0.144 (0.024–0.263) 0.018 0.149 (− 0.020–0.320) 0.085
<median − 0.006 (− 0.130–0.115) 0.927
AD signature cortical thickness >median 0.170 (0.050–0.290) 0.005 0.198 (0.030–0.365) 0.021
<median − 0.030 (− 0.146–0.090) 0.641
*Total GM volume >median 0.075 (− 0.044–0.194) 0.217 − 0.002 (− 0.172–0.170) 0.980
<median 0.077 (− 0.044–0.198) 0.212
*WML volume >median 0.054 (− 0.070–0.174) 0.379 − 0.110 (− 0.280–0.060) 0.208
<median 0.164 (0.042–0.290) 0.009
Memory (secondary outcome)
*Hippocampal volume >median 0.040 (− 0.107–0.190) 0.586 − 0.046 (− 0.257–0.166) 0.671
<median 0.087 (− 0.063–0.237) 0.256
AD signature cortical thickness >median 0.086 (− 0.062–0.234) 0.255 0.040 (− 0.168–0.250) 0.706
<median 0.046 (− 0.100–0.192) 0.539
*Total GM volume >median 0.010 (− 0.140–0.160) 0.891 − 0.113 (− 0.325–0.100) 0.297
<median 0.123 (− 0.028–0.270) 0.110
*WML volume >median 0.025 (− 0.130–0.179) 0.749 − 0.030 (− 0.248–0.190) 0.795
<median 0.054 (− 0.102–0.210) 0.497
Executive functioning (secondary outcome)
*Hippocampal volume >median 0.028 (− 0.073–0.128) 0.591 0.026 (− 0.117–0.170) 0.717
<median 0.001 (− 0.100–0.103) 0.982
AD signature cortical thickness >median 0.070 (− 0.035–0.169) 0.197 0.100 (− 0.042–0.240) 0.169
<median − 0.033 (− 0.134–0.070) 0.515
*Total GM volume >median − 0.006 (− 0.107–0.095) 0.909 − 0.048 (− 0.190–0.096) 0.514
<median 0.042 (− 0.060–0.144) 0.422
*WML volume >median 0.021 (− 0.085–0.128) 0.693 − 0.048(− 0.200–0.105) 0.540
<median 0.069 (− 0.039–0.178) 0.213
AD signature cortical thickness: cortical thickness in AD signature regions calculated as the average of cortical thickness in entorhinal, inferior temporal, middle
temporal, and fusiform regions as previously described [38]
NTB neuropsychological test battery, GM gray matter, WML white matter lesions
*For all volumetric measures, medians of TIV-normalized values were used
Values in bold represent p-value < 0.05; values in italics represent p-value < 0.10
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developing the first global network of dementia preven-
tion trials based on the FINGER model [43]. Results
from the FINGER MRI exploratory sub-study provide a
first reference frame for incorporating MRI outcomes
into such large-scale trial networks and offer a hypoth-
esis that can be confirmed or refuted in future trials.
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